(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say - 2Figure out How to Alter Your Volvo XC40 for Further developed Solace
- 3Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- 4Nestlé recalls infant formula in 49 countries. See list.
- 5Parents speak out as 4-year-old fights button battery injury in intensive care unit
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- FDA approves Wegovy pill for weight loss
- A Manual for Nations to Head out To
- Share your pick for the tree that you love for its novel magnificence!
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Gartex Texprocess India to showcase innovations across textile ecosystem
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Understanding the Rudiments of Tree Administrations
